An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium.
作者信息
Seifirad Soroush
机构信息
Department of Pediatric Cardiology, Children's Medical Center, Tehran University of Medical Sciences Tehran, Iran ; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran, Iran.
出版信息
Front Physiol. 2014 Feb 11;5:44. doi: 10.3389/fphys.2014.00044. eCollection 2014.
Abstract
摘要
相似文献
1
An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium.
Front Physiol. 2014 Feb 11;5:44. doi: 10.3389/fphys.2014.00044. eCollection 2014.
2
High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction.
J Cardiovasc Pharmacol. 2006 Jun;47(6):736-41. doi: 10.1097/01.fjc.0000211766.59636.0d.
3
Divergent Effects of Cyclophilin-D Inhibition on the Female Rat Heart: Acute Versus Chronic Post-Myocardial Infarction.
Cell Physiol Biochem. 2018;50(1):288-303. doi: 10.1159/000494006. Epub 2018 Oct 3.
4
Experimental acute myocardial infarction in rats: HIF-1α, caspase-3, erythropoietin and erythropoietin receptor expression and the cardioprotective effects of two different erythropoietin doses.
Acta Histochem. 2013 Sep;115(7):658-68. doi: 10.1016/j.acthis.2013.01.005. Epub 2013 Feb 26.
5
Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats.
Pharmacol Res. 2016 Nov;113(Pt A):62-70. doi: 10.1016/j.phrs.2016.08.013. Epub 2016 Aug 10.
6
Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters.
J Cardiovasc Pharmacol Ther. 2002 Apr;7(2):95-107. doi: 10.1177/107424840200700206.
7
Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction.
Int J Cardiol. 2013 May 10;165(2):291-8. doi: 10.1016/j.ijcard.2011.08.078. Epub 2011 Sep 22.
8
Identification of myocardial reperfusion with echo planar magnetic resonance imaging. Discrimination between occlusive and reperfused infarctions.
Circulation. 1994 Sep;90(3):1492-501. doi: 10.1161/01.cir.90.3.1492.
9
Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts.
J Biol Chem. 2004 May 14;279(20):20655-62. doi: 10.1074/jbc.M314099200. Epub 2004 Mar 11.
10
A Translational Study of a New Therapeutic Approach for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin into Reperfused Myocardium Reduces Ischemia-Reperfusion Injury in a Preclinical Porcine Model.
PLoS One. 2016 Sep 7;11(9):e0162425. doi: 10.1371/journal.pone.0162425. eCollection 2016.
引用本文的文献
1
Are There Any Cardioprotective Effects or Safety Concerns of Erythropoietin in Patients With Myocardial Infarction? A Systematic Review.
Cureus. 2022 Jun 5;14(6):e25671. doi: 10.7759/cureus.25671. eCollection 2022 Jun.
2
Inappropriate modeling of chronic and complex disorders: How to reconsider the approach in the context of predictive, preventive and personalized medicine, and translational medicine.
EPMA J. 2019 Jul 31;10(3):195-209. doi: 10.1007/s13167-019-00176-z. eCollection 2019 Sep.
3
Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.
BMC Cardiovasc Disord. 2017 Jan 21;17(1):38. doi: 10.1186/s12872-016-0464-3.
4
The antioxidants dilemma: are they potentially immunosuppressants and carcinogens?
Front Physiol. 2014 Jul 14;5:245. doi: 10.3389/fphys.2014.00245. eCollection 2014.
本文引用的文献
1
Microfabrication of human organs-on-chips.
Nat Protoc. 2013 Nov;8(11):2135-57. doi: 10.1038/nprot.2013.137. Epub 2013 Oct 10.
2
What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials.
Cardiovasc Drugs Ther. 2013 Aug;27(4):315-31. doi: 10.1007/s10557-013-6461-1.
3
Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: results of the randomized Intra-Co-EpoMI trial.
Arch Cardiovasc Dis. 2013 Mar;106(3):135-45. doi: 10.1016/j.acvd.2012.12.001. Epub 2013 Feb 1.
4
Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.
Am Heart J. 2012 Nov;164(5):715-727.e1. doi: 10.1016/j.ahj.2012.07.031. Epub 2012 Oct 16.
5
Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.
Nefrologia. 2012 May 14;32(3):343-52. doi: 10.3265/Nefrologia.pre2012.Jan.11111. Epub 2012 Apr 17.
6
Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?
PLoS One. 2012;7(4):e34819. doi: 10.1371/journal.pone.0034819. Epub 2012 Apr 18.
7
Animal models of atherosclerosis.
Arterioscler Thromb Vasc Biol. 2012 May;32(5):1104-15. doi: 10.1161/ATVBAHA.111.237693. Epub 2012 Mar 1.
8
Factors predicting erythropoietin resistance among maintenance hemodialysis patients.
Blood Purif. 2012;33(4):238-44. doi: 10.1159/000335256. Epub 2012 Feb 22.
9
Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.
Am Heart J. 2012 Feb;163(2):200-7.e1. doi: 10.1016/j.ahj.2011.11.005.
10
Animal models of atherosclerosis.
Prog Mol Biol Transl Sci. 2012;105:1-23. doi: 10.1016/B978-0-12-394596-9.00001-9.
Zotero 插件